

# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

	APPLICATION NO.	FI	LING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
	10/820,582	(	04/07/2004	Roger A. Sabbadini	078853-0311	8568
	35938	7590 08/29/2006			EXAMINER	
	BIOTECHN C/O PORTF		LAW GROUP	TATE, CHRISTO	TATE, CHRISTOPHER ROBIN	
	PO BOX 520	)50			ART UNIT	PAPER NUMBER
	MINNEAPOLIS, MN 55402				1655	

DATE MAILED: 08/29/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
Supplemental	10/820,582	SABBADINI, ROGER A.
Notice of Allowability	Examiner	Art Unit
	Christopher R. Tate	1655
The MAILING DATE of this communication appropriate All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT R of the Office or upon petition by the applicant. See 37 CFR 1.313.  1. This communication is responsive to the reply with amendation is responsive to the reply with amendation and the reply with amendation is responsive to the reply with amendation and the rep	ears on the cover sheet with the of (OR REMAINS) CLOSED in this application is subject 3 and MPEP 1308.  Idments filed 12 June 2006.  Inder 35 U.S.C. § 119(a)-(d) or (f).  The been received.  The been received in Application No  The been received in this application.  The been received in this application.	correspondence address polication. If not included n will be mailed in due course. THIS to withdrawal from issue at the initiative  a national stage application from the complying with the requirements  R'S AMENDMENT or NOTICE OF ation is deficient.
Paper No./Mail Date		
Identifying indicia such as the application number (see 37 CFR 1 each sheet. Replacement sheet(s) should be labeled as such in t		
6. DEPOSIT OF and/or INFORMATION about the deposit attached Examiner's comment regarding REQUIREMENT		
Attachment(s)  1.  Notice of References Cited (PTO-892)  2.  Notice of Draftperson's Patent Drawing Review (PTO-948)		Patent Application (PTO-152) / (PTO-413),
	Paper No./Mail Da	ate
<ol> <li>Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date</li> </ol>		
4.   Examiner's Comment Regarding Requirement for Deposit of Biological Material		ent of Reasons for Allowance
	0 D Othor	

9. Other \_\_\_\_.

Application/Control Number: 10/820,582 Page 2

Art Unit: 1655

## Examiner's Comments

This Supplemental Notice of Allowance is to correct minor typographical errors concerning claims 16 and 17 (as recited in the previous Office action). The previous Examiner's Amendment to the claims is being replaced by the below Examiner's Amendment to the claims.

### Examiner's Amendment

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Daniel Chambers on 26 June 2006.

## IN THE CLAIMS:

Claims 1, 2, 5, 6, and 7 have been canceled without prejudice.

The following new claims, claims 16 and 17, have been added:

- 16. A method for treating cancer in a patient comprising administering to the patient an agent that specifically binds to sphingosine-1-phosphate (S-1-P) in an amount effective to reduce the available concentration of S-1-P in the patient, whereby the agent treats the cancer.
- 17. The method according to claim 1, wherein said agent is an antibody derivative that specifically binds to S-1-P.

Art Unit: 1655

#### Conclusion

Claims 16 and 17 are allowed.

The prior art made of record and not relied upon is considered pertinent to applicant's disclosure.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christopher R. Tate whose telephone number is (571) 272-0970. The examiner can normally be reached on Mon-Thur, 6:30-4:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Terry McKelvey can be reached on (571) 272-0775. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Christopher R. Tate Primary Examiner Art Unit 1655